ID: ALA44412

Max Phase: Preclinical

Molecular Formula: C20H22N2O

Molecular Weight: 306.41

Molecule Type: Small molecule

Representations

Canonical SMILES:  Oc1ccc(CCCN2CCc3c([nH]c4ccccc34)C2)cc1

Standard InChI:  InChI=1S/C20H22N2O/c23-16-9-7-15(8-10-16)4-3-12-22-13-11-18-17-5-1-2-6-19(17)21-20(18)14-22/h1-2,5-10,21,23H,3-4,11-14H2

Standard InChI Key:  NVPKBSOCBDWMOI-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 306.41

Molecular Weight (Monoisotopic): 306.1732

AlogP: 3.86

#Rotatable Bonds: 4

Polar Surface Area: 39.26

Molecular Species: NEUTRAL

HBA: 2

HBD: 2

#RO5 Violations: 0

HBA (Lipinski): 3

HBD (Lipinski): 2

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 10.30

CX Basic pKa: 7.27

CX LogP: 4.13

CX LogD: 3.88

Aromatic Rings: 3

Heavy Atoms: 23

QED Weighted: 0.77

Np Likeness Score: -0.31

References

1. Tamiz AP, Whittemore ER, Woodward RM, Upasani RB, Keana JF..  (1999)  Structure-activity relationship for a series of 2-substituted 1,2,3,4-tetrahydro-9H-pyrido[3,4-b]indoles: potent subtype-selective inhibitors of N-methyl-D-aspartate (NMDA) receptors.,  9  (11): [PMID:10386947] [10.1016/s0960-894x(99)00248-6]

2. Beato A, Gori A, Boucherle B, Peuchmaur M, Haudecoeur R..  (2021)  β-Carboline as a Privileged Scaffold for Multitarget Strategies in Alzheimer's Disease Therapy.,  64  (3.0): [PMID:33528252] [10.1021/acs.jmedchem.0c01887]

Source

Source(1):

• Scientific Literature